ClinicalTrials.gg
CompletedNCT03139903NANPIMUpdated Nov 20, 2017

The Primordial Dwarfisms: Diagnosis, Identification of the Molecular Basis of Seckel Syndrome and Microcephalic Osteodysplastic Primordial Dwarfism Type II

An observational study in Microcephalic Osteodysplastic Primordial Dwarfism Type II and Seckel Syndrome, sponsored by Assistance Publique - Hôpitaux de Paris. Completed at 1 site in France. Open to participants aged 2 Months and older, including healthy volunteers. Per ClinicalTrials.gov, last updated 2017-11-20.

Sponsored by Assistance Publique - Hôpitaux de Paris · Observational

How we know

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Study type
Observational
Model
Family-based
Time perspective
Retrospective
Enrollment
30
Ages
2 Months and older
Sex
All
01

Study summary

The purpose of this study si to define morphological and epidemiological parameters and identify new symptoms in French patients with Seckel syndrome (SCKL) or microcephalic osteodysplastic primordial dwarfism type II (MOPDII).

Read the detailed description

Multicentre study, aiming to determine morphological and epidemiological parameters and identify new symptoms in French patients with SCKL or MOPDII.

At pre-inclusion visit: Realization of the photographs of: the face, entire body and the extremities (hands and feet) that will be serve for the collegiate decision of the inclusion or not of patients.

Patients are seen at inclusion V1 , a second visit V2 at 6-10 months after V1 and an annual follow-up visit.

At inclusion:

  • Full Clinical Examination, specialized consultations (Otorhinolaryngology, stomatology, orthopedics, ophthalmology)
  • Results of x-ray examinations and biological tests
  • Assessment of the patients competencies and initiation of appropriate care ( orthophony and psychomotricity...)
  • Assessment of intelligence and cognitive ability according the WISC-IV scale
  • Blood testing for diagnosis and research.

Visit 2:

  • Full Clinical Examination
  • Cerebral angiography-MRI for all patients
  • Programming a neurosurgery / neurovascular consultation based on MRI results
  • Immuno-hematology and hepato-gastroenterology consultation if anomaly during the visit V1

Annual follow-up visit:

  • Assessment of the complications of the disease and its clinical care
  • Full clinical examination
  • Skeletal x-ray and systematic orthopedic consultation
  • Blood Check
  • Prescription of tests if necessary depending to the complications identified of the disease
  • Reevaluation of the care according to the detected symptoms
02

Conditions studied

  • Microcephalic Osteodysplastic Primordial Dwarfism Type II
  • Seckel Syndrome

Keywords

  • Seckel Syndrome
  • Microcephalic Osteodysplastic Primordial Dwarfism Type II
03

In context

Lead sponsor

Assistance Publique - Hôpitaux de Paris is the lead sponsor of 3,598 studies on the registry; 1,038 are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
2 Months and older
Sexes eligible
All
Accepts healthy volunteers
Yes
Sampling method
Probability sample

Study population

Patients with Primordial Dwarfisms have been followed by network geneticists for which there is no systematic and homogeneous collection of biological, radiological and clinical data

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

Patients aged from 2 months to 50 years must present all of the following criteria:

  • Symmetrical intrauterine growth restriction (IUGR) \< - 2 DS, Birth size \<-2 DS and Cranial perimeter of birth \<-2 DS
  • Postnatal growth restriction (size \<-4DS)
  • Microcephaly \<-4DS
  • Clinical Diagnosis of Seckel Syndrome or Microcephalic osteodysplastic primordial dwarfism type II (MOPDII) by a geneticist
  • Having given free and

Exclusion criteria

Exclusion Criteria:

  • Refutation of the diagnosis
  • Parents' refusal to participate in genetic studies once the diagnosis of SCKL or MOPDII has been establish for the patient (major or minor)
  • Allergy to gadolinium, contraindicating the realization of an Angio-MRI
  • Absence of affiliation to a social security scheme or Universal Health Coverage.
Terms in these criteria, in plain language(1)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

05

Study design

Observational model
Family-based
Time perspective
Retrospective
Enrollment
30 participants (actual)
Patient registry
No
06

What researchers measure

Primary outcomes

  1. to visualize any vascular abnormalities according the cerebral angiography-MRI

    Time frame: 10 months

Secondary outcomes

  1. Assessment of intelligence and cognitive ability according the Wechsler Intelligence Scale for Children (WISC-IV)

    Time frame: 2 days

  2. Measurement of visual acuity

    Time frame: 2 days

07

Study locations

1 site
  • Medical Genetics Department and INSERM U781, Necker-Enfants Malades Hospital
    Paris, 75743, France
08

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Ran from Jul 2010 to primary completion in Jul 2013, 35 months.

How these figures are worked out, and which studies are left out of them.

Registered
Mar 23, 2017
First posted
May 4, 2017
StartActual
Jul 28, 2010
Primary completionActual
Jul 16, 2013
CompletionActual
Jul 2015
Last update
Nov 20, 2017
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Nov 20, 2017, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT03139903
Responsible party
Sponsor
First posted
May 4, 2017
Start date
Jul 28, 2010
Primary completion
Jul 16, 2013
Completion
Jul 2015
Last update
Nov 20, 2017

Study contacts

CORMIER-DAIRE Valérie, PhD
principal investigator · Medical Genetics Department and INSERM U781, Necker-Enfants Malades Hospital, 75743 Paris, France

Oversight

Data monitoring committee
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Nov 2017. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion